SCHEMBL6310229

SCHEMBL6310229

Cc1noc2c1CCCc1[nH]cc(C(=O)Nc3cnccn3)c1-2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
RAB9A P51151 7/20 0.35
NPC1 O15118 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 2/20 0.34
PKM P14618 1/20 0.34
TRPV4 Q9HBA0 1/20 0.33
NOTUM Q6P988 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302557 0.86 NPC1 (0.49) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6833400 0.78 TRPV4 (0.35) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6304587 0.78 HCAR2 (0.33) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6302913 0.75 KMT2A (0.36) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6302879 0.74 KMT2A (0.37) KMT2ARAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6305153 0.74 KDM4E (0.42) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL6309979 0.73 SMN1; SMN2 (0.40) KMT2ARAB9ANPC1SMN1; SMN2LMNA
SCHEMBL6834466 0.73 KMT2A (0.37) KMT2ARAB9ANPC1SMN1; SMN2TSHR
SCHEMBL6310478 0.71 KMT2A (0.38) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6305014 0.67 RAB9A (0.36) KMT2ARAB9ANPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 US claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
US-6949562-B2 Heterocyclic compounds as ligands of the GABAA receptor NEUROGEN CORPORATION (US) 2005-09-27 US disclosed
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885MEN1 2641/4885RAB9A 962/4885
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885MEN1 2641/4885RAB9A 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.